| Ident. | Authors (with country if any) | Title |
|---|
| 000541 (2020) |
Sebastian E. Sattui [États-Unis] ; Jean W. Liew [États-Unis] ; Elizabeth R. Graef [États-Unis] ; Ariella Coler-Reilly [États-Unis] ; Francis Berenbaum [France] ; Alí Duarte-García [États-Unis] ; Carly Harrison [États-Unis] ; Maximilian F. Konig [États-Unis] ; Peter Korsten [Allemagne] ; Michael S. Putman [États-Unis] ; Philip C. Robinson [Australie] ; Emily Sirotich [Canada] ; Manuel F. Ugarte-Gil [Pérou] ; Kate Webb [Afrique du Sud, Royaume-Uni] ; Kristen J. Young [États-Unis] ; Alfred H J. Kim [États-Unis] ; Jeffrey A. Sparks [États-Unis] | Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. |
| 000621 (2020) |
Atul Sharma [Australie] ; Swapnil Tiwari [Inde] ; Manas Kanti Deb [Inde] ; Jean Louis Marty [France] | Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. |
| 000622 (2020) |
Sébastien Nisole [France] ; Aure Saulnier ; Anne Gatignol [Canada] | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease? |
| 000700 (2020) |
Daria Sicari [France, Italie] ; Aristotelis Chatziioannou [Grèce] ; Theodoros Koutsandreas [Grèce] ; Roberto Sitia [Italie] ; Eric Chevet [France, Italie] | Role of the early secretory pathway in SARS-CoV-2 infection. |
| 000718 (2020) |
P C Fragkou [Suisse] ; D. Belhadi [France] ; N. Peiffer-Smadja [France] ; C D Moschopoulos [Grèce] ; F-X Lescure [France] ; H. Janocha [Allemagne] ; E. Karofylakis [Grèce] ; Y. Yazdanpanah [France] ; F. Mentré [France] ; C. Skevaki [Allemagne] ; C. Laouénan [France] ; S. Tsiodras [Suisse] | Review of trials currently testing treatment and prevention of COVID-19. |
| 000759 (2020) |
M. Plaze [France] ; D. Attali [France] ; A-C Petit [France] ; M. Blatzer [France] ; E. Simon-Loriere [France] ; F. Vinckier [France] ; A. Cachia [France] ; F. Chrétien [France] ; R. Gaillard [France] | Repurposing chlorpromazine to treat COVID-19: The reCoVery study. |
| 000774 (2020) |
Ashleigh Shannon [France] ; Nhung Thi-Tuyet Le [France] ; Barbara Selisko [France] ; Cecilia Eydoux [France] ; Karine Alvarez [France] ; Jean-Claude Guillemot [France] ; Etienne Decroly [France] ; Olve Peersen [France] ; Francois Ferron [France] ; Bruno Canard [France] | Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. |
| 000776 (2020) |
Alan G. Fraser [Royaume-Uni, Belgique] ; Piotr Szyma Ski [Pologne] ; Elizabeth Macintyre [France] ; Martin Landray [Royaume-Uni] | Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic? |
| 000820 (2020) |
Marc Montana [France] ; Vincent Montero [France] ; Omar Khoumeri [France] ; Patrice Vanelle [France] | Quinoxaline Derivatives as Antiviral Agents: A Systematic Review. |
| 000889 (2020) |
S. Tunesi [France] ; A. Bourgarit [France] | Prescribing COVID-19 treatments: what we should never forget. |
| 000921 (2020) |
Nicolas Venisse [France] | Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. |
| 000922 (2020) |
Florian Lemaitre [France] ; Caroline Solas [France] ; Matthieu Grégoire [France] ; Laurence Lagarce [France] ; Laure Elens [Belgique] ; Elisabeth Polard [France] ; Béatrice Saint-Salvi [France] ; Agnès Sommet [France] ; Michel Tod [France] ; Chantal Barin-Le Guellec [France] | Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. |
| 000949 (2020) |
Behnood Bikdeli [États-Unis] ; Mahesh V. Madhavan [États-Unis] ; Aakriti Gupta [États-Unis] ; David Jimenez [Espagne] ; John R. Burton [États-Unis] ; Caroline Der Nigoghossian [États-Unis] ; Taylor Chuich [États-Unis] ; Shayan Nabavi Nouri [États-Unis] ; Isaac Dreyfus [États-Unis] ; Elissa Driggin [États-Unis] ; Sanjum Sethi [États-Unis] ; Kartik Sehgal [États-Unis] ; Saurav Chatterjee [États-Unis] ; Walter Ageno [Italie] ; Mohammad Madjid [États-Unis] ; Yutao Guo [République populaire de Chine, Royaume-Uni] ; Liang V. Tang [République populaire de Chine] ; Yu Hu [République populaire de Chine] ; Laurent Bertoletti [France] ; Jay Giri [États-Unis] ; Mary Cushman [États-Unis] ; Isabelle Quéré [France] ; Evangelos P. Dimakakos [Grèce] ; C Michael Gibson [États-Unis] ; Giuseppe Lippi [Italie] ; Emmanuel J. Favaloro [Australie] ; Jawed Fareed [États-Unis] ; Alfonso J. Tafur [États-Unis] ; Dominic P. Francese [États-Unis] ; Jaya Batra [États-Unis] ; Anna Falanga [Italie] ; Kevin J. Clerkin [États-Unis] ; Nir Uriel [États-Unis] ; Ajay Kirtane [États-Unis] ; Claire Mclintock [Nouvelle-Zélande] ; Beverley J. Hunt [Royaume-Uni] ; Alex C. Spyropoulos [États-Unis] ; Geoffrey D. Barnes [États-Unis] ; John W. Eikelboom [Canada] ; Ido Weinberg [États-Unis] ; Sam Schulman [Russie, Canada] ; Marc Carrier [Canada] ; Gregory Piazza [États-Unis] ; Joshua A. Beckman [États-Unis] ; Martin B. Leon [États-Unis] ; Gregg W. Stone [États-Unis] ; Stephan Rosenkranz [Allemagne] ; Samuel Z. Goldhaber [États-Unis] ; Sahil A. Parikh [États-Unis] ; Manuel Monreal [Espagne] ; Harlan M. Krumholz [États-Unis] ; Stavros V. Konstantinides [Allemagne] ; Jeffrey I. Weitz [Canada] ; Gregory Y H. Lip [Royaume-Uni, Danemark] | Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. |
| 000950 (2020) |
Laure Elens [Belgique] ; Loralie J. Langman [États-Unis] ; Dennis A. Hesselink [Pays-Bas] ; Stein Bergan [Norvège] ; Dirk Jan A R. Moes [Pays-Bas] ; Mariadelfina Molinaro [Italie] ; Raman Venkataramanan [États-Unis] ; Florian Lemaitre [France] | Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. |
| 000996 (2020) |
Amélie Soumier [France] ; Angela Sirigu [France] | Oxytocin as a potential defence against Covid-19? |
| 000A15 (2020) |
Allan Sauvat [France] ; Fabiola Ciccosanti [Italie] ; Francesca Colavita [Italie] ; Martina Di Rienzo [Italie] ; Concetta Castilletti [Italie] ; Maria Rosaria Capobianchi [Italie] ; Oliver Kepp [France] ; Laurence Zitvogel [France, République populaire de Chine] ; Gian Maria Fimia [Italie] ; Mauro Piacentini [Italie] ; Guido Kroemer [France, République populaire de Chine, Suède] | On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. |
| 000A31 (2020) |
Franck Touret [France] ; Xavier De Lamballerie [France] | Of chloroquine and COVID-19. |
| 000A53 (2020) |
J M Molina [France] ; C. Delaugerre [France] ; J. Le Goff [France] ; B. Mela-Lima [France] ; D. Ponscarme [France] ; L. Goldwirt [France] ; N. De Castro [France] | No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. |
| 000A60 (2020) |
Christian A. Devaux [France] ; Jean-Marc Rolain [France] ; Philippe Colson [France] ; Didier Raoult [France] | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| 000B08 (2020) |
Roberto Gomeni [France] ; Tianhong Xu [République populaire de Chine] ; Xuejuan Gao [République populaire de Chine] ; Françoise Bressolle-Gomeni [France] | Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2. |
| 000B26 (2020) |
Abdelouaheb Benani [Maroc] ; Sanae Ben Mkaddem [France] | Mechanisms Underlying Potential Therapeutic Approaches for COVID-19. |
